Quarterly Result5 May 2026, 07:41 pm
Jenburkt Pharma: FY26 Revenue at ₹168.74 Cr, Up 11.24% YoY
AI Summary
Jenburkt Pharmaceuticals Ltd's standalone audited financial results for the year ended March 31, 2026, show a revenue from operations of ₹16874.06 Lacs, an increase from ₹15169.15 Lacs in the previous year. The company's Board of Directors approved a dividend of ₹220.70 per equity share. Shri Dilip H. Bhuta was re-appointed as the Whole Time Director and CFO for five years, effective April 1, 2027. The 41st Annual General Meeting is scheduled for September 4, 2026, via video conferencing.
Key Highlights
- FY26 revenue from operations reached ₹16874.06 Lacs, up from ₹15169.15 Lacs YoY.
- Board approved a dividend of ₹220.70 per equity share for FY26.
- Dilip H. Bhuta re-appointed as Whole Time Director and CFO for five years.
- 41st Annual General Meeting scheduled for September 4, 2026, via VC.
- Auditors presented an unmodified opinion on the financial statements.